Here are the 424B prospectus supplements from SciSparc Ltd. (SPRC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SPRC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPRC filings page.
SciSparc Ltd. is issuing 766,170 ordinary shares in a registered direct offering at $1.00 per share, for estimated net proceeds of about $0.7 million after offering expenses. Shares outstanding were 3,584,331 as of January 13, 2026 and are expected to be 4,350,501 after the sale.
The company plans to use the cash for working capital, including research and development, general corporate purposes, and potential strategic investments that may differ from its current business focus. Recent developments include a non-binding term sheet for its majority-owned subsidiary NeuroThera to acquire 55% of a quantum computing bio data analytics company, and an agreement for SciSparc to acquire the MUSE endoscopic IP portfolio from Xylo in exchange for shares (or pre-funded warrants) equal to 19.99% of its outstanding equity.
The document highlights significant risks, including potential dilution, an auditor going-concern paragraph, and a Nasdaq notice that the company fell below the $2.5 million stockholders’ equity requirement, creating a risk of delisting if compliance is not restored.